- 收听数
- 0
- 性别
- 保密
- 听众数
- 18
- 最后登录
- 2021-3-22
- QQ
 - UID
- 765
- 阅读权限
- 20
- 帖子
- 1283
- 精华
- 0
- 在线时间
- 411 小时
- 注册时间
- 2012-10-21

- 科研币
- 7
- 速递币
- 271
- 娱乐币
- 2897
- 文献值
- 0
- 资源值
- 0
- 贡献值
- 0
|
10速递币
题名 | Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. | 作者 | Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B. | 杂志 | Eur Urol. 2013 Aug 15. pii: S0302-2838(13)00831-2. doi: 10.1016/j.eururo.2013.08.010. [Epub ahead of print] | 链接 | http://www.ncbi.nlm.nih.gov/pubmed/?term=Tumor+Growth+Rate+Provides+Useful+Information+to+Evaluate+Sorafenib+and+Everolimus+Treatment+in+Metastatic+Renal+Cell+Carcinoma+Patients%3A+An+Integrated+Analysis+of+the+TARGET+and+RECORD+Phase+3+Trial+Data |
|
|